Orianne Dumas1, Kohei Hasegawa2, Jonathan M Mansbach3, Ashley F Sullivan2, Pedro A Piedra4, Carlos A Camargo2. 1. INSERM, U1168, VIMA: Aging and Chronic Diseases, Epidemiological and Public Health Approaches, F-94807, Villejuif, France; Univ Versailles St-Quentin-en-Yvelines, UMR-S 1168, F-78180, Montigny le Bretonneux, France. Electronic address: orianne.dumas@inserm.fr. 2. Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass. 3. Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Mass. 4. Departments of Molecular Virology and Microbiology and Pediatrics, Baylor College of Medicine, Houston, Tex.
Abstract
BACKGROUND: A better understanding of bronchiolitis heterogeneity might help clarify its relationship with the development of recurrent wheezing and asthma. OBJECTIVES: We sought to identify severe bronchiolitis profiles using a clustering approach and to investigate for the first time their association with allergy/inflammatory biomarkers, nasopharyngeal microbiota, and development of recurrent wheezing by age 3 years. METHODS: We analyzed data from a prospective, 17-center US cohort study of 921 infants (age <1 year) hospitalized with bronchiolitis (2011-2014 winters) with posthospitalization follow-up. Severe bronchiolitis profiles at baseline (hospitalization) were determined by using latent class analysis based on clinical factors and viral etiology. Blood biomarkers and nasopharyngeal microbiota profiles were determined by using samples collected within 24 hours of hospitalization. Recurrent wheezing by age 3 years was defined based on parental report of breathing problem episodes after discharge. RESULTS: Three severe bronchiolitis profiles were identified: profile A (15%), which was characterized by a history of breathing problems/eczema during infancy and non-respiratory syncytial virus (mostly rhinovirus) infection; profile B (49%), which has the largest probability of respiratory syncytial virus infection and resembled classic respiratory syncytial virus-induced bronchiolitis; and profile C (36%), which was composed of the most severely ill group. Profile A infants had higher eosinophil counts, higher cathelicidin levels, and increased proportions of Haemophilus-dominant or Moraxella-dominant microbiota profiles. Compared with profile B, we observed significantly increased risk of recurrent wheezing in children with profile A (hazard ratio, 2.64; 95% CI, 1.90-3.68) and, to a lesser extent, with profile C (hazard ratio, 1.51; 95% CI, 1.14-2.01). CONCLUSION: Although longer follow-up is needed, our results might help identify, among children hospitalized for bronchiolitis, subgroups with particularly increased risk of asthma.
BACKGROUND: A better understanding of bronchiolitis heterogeneity might help clarify its relationship with the development of recurrent wheezing and asthma. OBJECTIVES: We sought to identify severe bronchiolitis profiles using a clustering approach and to investigate for the first time their association with allergy/inflammatory biomarkers, nasopharyngeal microbiota, and development of recurrent wheezing by age 3 years. METHODS: We analyzed data from a prospective, 17-center US cohort study of 921 infants (age <1 year) hospitalized with bronchiolitis (2011-2014 winters) with posthospitalization follow-up. Severe bronchiolitis profiles at baseline (hospitalization) were determined by using latent class analysis based on clinical factors and viral etiology. Blood biomarkers and nasopharyngeal microbiota profiles were determined by using samples collected within 24 hours of hospitalization. Recurrent wheezing by age 3 years was defined based on parental report of breathing problem episodes after discharge. RESULTS: Three severe bronchiolitis profiles were identified: profile A (15%), which was characterized by a history of breathing problems/eczema during infancy and non-respiratory syncytial virus (mostly rhinovirus) infection; profile B (49%), which has the largest probability of respiratory syncytial virus infection and resembled classic respiratory syncytial virus-induced bronchiolitis; and profile C (36%), which was composed of the most severely ill group. Profile A infants had higher eosinophil counts, higher cathelicidin levels, and increased proportions of Haemophilus-dominant or Moraxella-dominant microbiota profiles. Compared with profile B, we observed significantly increased risk of recurrent wheezing in children with profile A (hazard ratio, 2.64; 95% CI, 1.90-3.68) and, to a lesser extent, with profile C (hazard ratio, 1.51; 95% CI, 1.14-2.01). CONCLUSION: Although longer follow-up is needed, our results might help identify, among children hospitalized for bronchiolitis, subgroups with particularly increased risk of asthma.
Authors: Stanley J Szefler; Sally Wenzel; Robert Brown; Serpil C Erzurum; John V Fahy; Robert G Hamilton; John F Hunt; Hirohito Kita; Andrew H Liu; Reynold A Panettieri; Robert P Schleimer; Michael Minnicozzi Journal: J Allergy Clin Immunol Date: 2012-03 Impact factor: 10.793
Authors: V Siroux; X Basagaña; A Boudier; I Pin; J Garcia-Aymerich; A Vesin; R Slama; D Jarvis; J M Anto; F Kauffmann; J Sunyer Journal: Eur Respir J Date: 2011-01-13 Impact factor: 16.671
Authors: Daniel J Jackson; Michael D Evans; Ronald E Gangnon; Christopher J Tisler; Tressa E Pappas; Wai-Ming Lee; James E Gern; Robert F Lemanske Journal: Am J Respir Crit Care Med Date: 2011-09-29 Impact factor: 21.405
Authors: Hans Bisgaard; Mette Northman Hermansen; Frederik Buchvald; Lotte Loland; Liselotte Brydensholt Halkjaer; Klaus Bønnelykke; Martin Brasholt; Andreas Heltberg; Nadja Hawwa Vissing; Sannie Vester Thorsen; Malene Stage; Christian Bressen Pipper Journal: N Engl J Med Date: 2007-10-11 Impact factor: 91.245
Authors: Kecia N Carroll; Pingsheng Wu; Tebeb Gebretsadik; Marie R Griffin; William D Dupont; Edward F Mitchel; Tina V Hartert Journal: J Allergy Clin Immunol Date: 2009-04-10 Impact factor: 10.793
Authors: Olga E Savenije; Raquel Granell; Daan Caudri; Gerard H Koppelman; Henriëtte A Smit; Alet Wijga; Johan C de Jongste; Bert Brunekreef; Jonathan A Sterne; Dirkje S Postma; John Henderson; Marjan Kerkhof Journal: J Allergy Clin Immunol Date: 2011-03-16 Impact factor: 10.793
Authors: J Henderson; R Granell; J Heron; A Sherriff; A Simpson; A Woodcock; D P Strachan; S O Shaheen; J A C Sterne Journal: Thorax Date: 2008-08-04 Impact factor: 9.102
Authors: Kohei Hasegawa; Tadahiro Goto; Atsushi Hirayama; Federico R Laham; Jonathan M Mansbach; Pedro A Piedra; Carlos A Camargo Journal: Pediatr Infect Dis J Date: 2019-08 Impact factor: 2.129
Authors: Carlos E Rodríguez-Martínez; Jose A Castro-Rodriguez; Gustavo Nino; Fabio Midulla Journal: Paediatr Respir Rev Date: 2019-04-12 Impact factor: 2.726
Authors: Michimasa Fujiogi; Carlos A Camargo; Yoshihiko Raita; Yury A Bochkov; James E Gern; Jonathan M Mansbach; Pedro A Piedra; Kohei Hasegawa Journal: Pediatr Allergy Immunol Date: 2020-06-10 Impact factor: 6.377
Authors: Elie J Mitri; David X Zheng; Vebhav Garg; Cassandra C Crifase; Nicole M Herrera; Janice A Espinola; Kohei Hasegawa; Carlos A Camargo Journal: Pediatr Pulmonol Date: 2021-06-25
Authors: Aubree C Honcoop; Patricia Poitevien; Ellen Kerns; Brian Alverson; Russell J McCulloh Journal: Acad Emerg Med Date: 2021-06-11 Impact factor: 5.221
Authors: Yoshihiko Raita; Marcos Pérez-Losada; Robert J Freishtat; Brennan Harmon; Jonathan M Mansbach; Pedro A Piedra; Zhaozhong Zhu; Carlos A Camargo; Kohei Hasegawa Journal: Nat Commun Date: 2021-06-14 Impact factor: 17.694
Authors: Yoshihiko Raita; Carlos A Camargo; Yury A Bochkov; Juan C Celedón; James E Gern; Jonathan M Mansbach; Eugene P Rhee; Robert J Freishtat; Kohei Hasegawa Journal: J Allergy Clin Immunol Date: 2020-11-13 Impact factor: 14.290